MedKoo Cat#: 465688 | Name: NCX-530

Description:

WARNING: This product is for research use only, not for human or veterinary use.

NCX-530, also known as NO-indomethacin, is a NO-releasing NSAID compound.

Chemical Structure

NCX-530
NCX-530
CAS#unknown

Theoretical Analysis

MedKoo Cat#: 465688

Name: NCX-530

CAS#: unknown

Chemical Formula: C26H21ClN2O7

Exact Mass: 508.1037

Molecular Weight: 508.91

Elemental Analysis: C, 61.36; H, 4.16; Cl, 6.97; N, 5.50; O, 22.01

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
NCX-530; NCX530; NCX 530; NO-indomethacin; NO indomethacin; NOindomethacin;
IUPAC/Chemical Name
3-((nitrooxy)methyl)phenyl 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)acetate
InChi Key
CDBYEQYEPGILFF-UHFFFAOYSA-N
InChi Code
InChI=1S/C26H21ClN2O7/c1-16-22(14-25(30)36-21-5-3-4-17(12-21)15-35-29(32)33)23-13-20(34-2)10-11-24(23)28(16)26(31)18-6-8-19(27)9-7-18/h3-13H,14-15H2,1-2H3
SMILES Code
COC1=CC2=C(N(C(C3=CC=C(Cl)C=C3)=O)C(C)=C2CC(OC4=CC(CO[N+]([O-])=O)=CC=C4)=O)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 508.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ragot T, Provost C, Prignon A, Cohen R, Lepoivre M, Lausson S. Apoptosis induction by combination of drugs or a conjugated molecule associating non- steroidal anti-inflammatory and nitric oxide donor effects in medullary thyroid cancer models: implication of the tumor suppressor p73. Thyroid Res. 2015 Aug 14;8:13. doi: 10.1186/s13044-015-0025-3. PMID: 26273323; PMCID: PMC4535850. 2: Kawaratani Y, Harada T, Hirata Y, Nagaoka Y, Tanimura S, Shibano M, Taniguchi M, Yasuda M, Baba K, Uesato S. New microtubule polymerization inhibitors comprising a nitrooxymethylphenyl group. Bioorg Med Chem. 2011 Jul 1;19(13):3995-4003. doi: 10.1016/j.bmc.2011.05.031. Epub 2011 May 23. PMID: 21664138. 3: Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, Patlolla JM, Simi B, Kopelovich L, Rigas B. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther. 2006 Jun;5(6):1530-8. doi: 10.1158/1535-7163.MCT-06-0061. PMID: 16818512. 4: Tomisato W, Tanaka K, Tsutsumi S, Hoshino T, Yokomizo K, Suzuki K, Katsu T, Mizushima T, Mizushima T. Low direct cytotoxicity and cytoprotective effects of nitric oxide releasing indomethacin. Dig Dis Sci. 2005 Oct;50(10):1927-37. doi: 10.1007/s10620-005-2963-4. PMID: 16187199. 5: Takeuchi K, Mizoguchi H, Araki H, Komoike Y, Suzuki K. Lack of gastric toxicity of nitric oxide-releasing indomethacin, NCX-530, in experimental animals. Dig Dis Sci. 2001 Aug;46(8):1805-18. doi: 10.1023/a:1010638528675. PMID: 11508687. 6: Mizoguchi H, Hase S, Tanaka A, Takeuchi K. Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX-530, in rats. Aliment Pharmacol Ther. 2001 Feb;15(2):257-67. doi: 10.1046/j.1365-2036.2001.00916.x. PMID: 11148446.